The last Zenith corporate update was almost 6 months ago on June 20, 2016. Other than the news release on June 15, 2016 announcing the start of ZEN-3694 dosing and the date of the June 20 corporate update presentation, the only other news release since then was on August 2, 2016 announcing the name change and corporate re-organization. The name change/reorganization announcement had been expected for a few months prior to it actually occuring, so it wasn't much of a surprise.
It goes without saying that we are all very anxious for a Zenith corporate update. ZEN-3694 dosing in its Phase 1 mCRPC trial has now finished its 6th 4-week dosing period by my estimation. It will be 6-months since start of dosing on the day of the Zenith AGM, December 15th. Based on previous company estimates, the ZEN-3694/enzalutamide combo therapy Phase 1 mCRPC trial should be starting in Q4 2016.
I asked Sarah via email yesterday if we will be getting a corporate update webcast after the AGM and she replied today "there will be a webcast corporate update for RVX and ZEN on Dec. 15th at the AGMs. Details will be published shortly."
BearDownAZ
